Logo

AbCellera: Andrew Booth, Tryn Stimart

Sep 06, 2019

AbCellera, a firm that levearges single-cell analysis technologies to discover and develop therapeutic antibodies, has named Andrew Booth as chief financial officer and Tryn Stimart as general counsel.

Booth joins AbCellera from Stemcell Technologies, where he held the roles of vice president of instrumentation, chief financial officer, and chief commercial officer. Prior to this he led mergers and acquisitions for GE Healthcare's Europe, Middle East, and Africa business and its global life sciences business.

Stimart joins AbCellera from law firm Gibbons PC, where he was a partner in the firm's New York office. Prior to this, he held positions as legal counsel at Finnegan LLP, Cooley LLP, and Womble Bond Dickinson LLP.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.